MAP2K7 and melanoma: BRAF is a serine-threonine kinase within the RAS-RAF-MEK-ERK pathway; approximately 50% of melanomas harbor BRAF V600 mutations resulting in constitutive activation of MEK and ERK, with BRAF V600E being the most commonly observed mutation (32).